

SECURITIES & EXCHANGE COMMISSION EDGAR FILING

Provectus Pharmaceuticals, Inc.

Form: 8-K

Date Filed: 2002-08-20

Corporate Issuer CIK: 315545

Symbol: PVCT

SIC Code: 2834

Fiscal Year End: 12/31

FORM 8-K**CURRENT REPORT****PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934**Date of Report (Date of earliest event reported): **August 7, 2002****PROVECTUS PHARMACEUTICALS, INC.**

(Exact Name of Registrant as Specified in Charter)

Nevada	0-9410	83-0233011
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File Number)	(I.R.S. Employer Identification Number)

7327 Oak Ridge Highway Suite B, Knoxville, Tennessee 37931

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: **865/769-4011****N/A**

(Former Name or Former Address, if Changed Since Last Report)

Item 1.

None, not applicable.

Item 2.

None, not applicable.

Item 3.

None, not applicable.

Item 4.

None, not applicable.

Item 5. Other Events.

Provectus Pharmaceuticals, Inc., a Nevada corporation (the "Company") issued a press release dated August 7, 2002 announcing its plans to acquire from its founders a therapeutics business to be created pursuant to a separation agreement between the founders and Photogen Technologies, Inc., a Nevada corporation. A copy of that news release is filed as Exhibit 99.1 to this Current Report on Form 8-K.

Item 6.

None, not applicable.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

(a)

(b)

(c) Exhibits.

Exhibits required by Item 601 of Regulation S-B are incorporated herein by reference and are listed on the attached Exhibit

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release of the Company dated August 7, 2002.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROVECTUS PHARMACEUTICALS, INC.

Dated: August 20, 2002 By: /s/ Timothy C. Scott

Timothy C. Scott

President

Press Release

Provectus Pharmaceuticals Plans to Acquire Therapeutic Business

KNOXVILLE, Tenn., August 7, 2002 - Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) today announced plans to acquire a therapeutic business that is to be created as a result of a separation agreement between Photogen Technologies (PHGN) and Photogen's five founding scientists.

The separation agreement, which has received Photogen board approval, must be ratified by a vote of its shareholders at its upcoming annual meeting. After ratification, the founding scientists intend to merge the therapeutics business into Provectus Pharmaceuticals.

"Acquisition of the therapeutics business via the Photogen split-off will complete our initial product portfolio in the areas of prescription drugs and medical devices" said Provectus CEO Craig Dees, Ph.D. "We should then be in the position to implement our entire product line in the areas of dermatology, oncology, biotechnology, medical devices, and over-the-counter (OTC) pharmaceuticals."

Provectus Pharmaceuticals consists of pharmaceutical products across three sectors of the healthcare industry: prescription drugs, medical devices and OTC pharmaceuticals.

The company's corporate offices and laboratory are located at 7327 Oak Ridge Highway Suite A, Knoxville, TN 37931; 865/769-4012. For more information, contact the company at info at provectuscorp.com or visit the corporate Web site: www.provectuscorp.com

This release and others issued or made from time to time by the company or its representatives contain portions that may constitute forward-looking statements. Those statements include comments regarding the intent, beliefs or current expectations of the company and members of its management team, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements.

Contact:

Provectus Pharmaceuticals Inc., Knoxville

Timothy C. Scott, 865/769-4012 (EDT)

or

Hilary Kaye Associates

Hilary Kaye, 714/426-0444 (Media/PDT)